JP2011521938A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011521938A5 JP2011521938A5 JP2011511094A JP2011511094A JP2011521938A5 JP 2011521938 A5 JP2011521938 A5 JP 2011521938A5 JP 2011511094 A JP2011511094 A JP 2011511094A JP 2011511094 A JP2011511094 A JP 2011511094A JP 2011521938 A5 JP2011521938 A5 JP 2011521938A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- heterocyclyl
- heteroaryl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 216
- 125000003545 alkoxy group Chemical group 0.000 claims 55
- 125000000623 heterocyclic group Chemical group 0.000 claims 53
- 125000001072 heteroaryl group Chemical group 0.000 claims 41
- 229910052739 hydrogen Inorganic materials 0.000 claims 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 32
- 125000003118 aryl group Chemical group 0.000 claims 28
- -1 cyano, hydroxy Chemical group 0.000 claims 27
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 150000002367 halogens Chemical class 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000002431 hydrogen Chemical class 0.000 claims 14
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 7
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 3
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000003637 steroidlike Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims 1
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 claims 1
- 102000009410 Chemokine receptor Human genes 0.000 claims 1
- 108050000299 Chemokine receptor Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12893908P | 2008-05-27 | 2008-05-27 | |
| US61/128,939 | 2008-05-27 | ||
| PCT/GB2009/050566 WO2009144494A1 (en) | 2008-05-27 | 2009-05-26 | Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011521938A JP2011521938A (ja) | 2011-07-28 |
| JP2011521938A5 true JP2011521938A5 (enExample) | 2013-05-09 |
| JP5607032B2 JP5607032B2 (ja) | 2014-10-15 |
Family
ID=40821676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011511094A Expired - Fee Related JP5607032B2 (ja) | 2008-05-27 | 2009-05-26 | フェノキシピリジニルアミド誘導体およびｐｄｅ４仲介疾患状態におけるその使用 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8273774B2 (enExample) |
| EP (2) | EP2297106B1 (enExample) |
| JP (1) | JP5607032B2 (enExample) |
| KR (1) | KR101605576B1 (enExample) |
| CN (1) | CN102105448B (enExample) |
| AR (1) | AR071920A1 (enExample) |
| AU (1) | AU2009252938B2 (enExample) |
| BR (1) | BRPI0912103A2 (enExample) |
| CA (1) | CA2721065C (enExample) |
| CL (1) | CL2009001298A1 (enExample) |
| CY (1) | CY1115566T1 (enExample) |
| DK (1) | DK2297106T3 (enExample) |
| ES (1) | ES2502527T3 (enExample) |
| HK (1) | HK1203482A1 (enExample) |
| HR (1) | HRP20140884T1 (enExample) |
| MX (1) | MX2010012492A (enExample) |
| PE (1) | PE20100144A1 (enExample) |
| PL (1) | PL2297106T3 (enExample) |
| PT (1) | PT2297106E (enExample) |
| RU (1) | RU2509077C2 (enExample) |
| SI (1) | SI2297106T1 (enExample) |
| TW (1) | TW200951139A (enExample) |
| UY (1) | UY31849A (enExample) |
| WO (1) | WO2009144494A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI546537B (zh) * | 2009-05-19 | 2016-08-21 | 維維亞生技公司 | 提供針對血液腫瘤之體外個人化藥物測試之方法 |
| US9073820B2 (en) | 2011-11-04 | 2015-07-07 | Oregon Health & Science University | Pharmaceutical compositions comprising napthamides |
| US10106510B2 (en) | 2014-09-10 | 2018-10-23 | Epizyme, Inc. | Substituted isoxazoles for treating cancer |
| WO2017089347A1 (en) | 2015-11-25 | 2017-06-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas |
| CN113332292A (zh) * | 2016-02-23 | 2021-09-03 | 辉瑞公司 | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 |
| FI3851436T3 (fi) | 2018-09-10 | 2024-09-03 | Kaken Pharma Co Ltd | Uusi heteroaromaattinen amidijohdannainen ja sitä sisältävä lääke |
| WO2020179859A1 (ja) | 2019-03-06 | 2020-09-10 | 第一三共株式会社 | ピロロピラゾール誘導体 |
| EP3782702A1 (en) * | 2019-08-21 | 2021-02-24 | AC BioScience SA | Compounds and use thereof for the treatment of infectious diseases and cancer |
| KR102271305B1 (ko) | 2020-05-21 | 2021-06-30 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| KR102272907B1 (ko) | 2020-11-05 | 2021-07-05 | 주식회사 아리바이오 | 치매 예방 및 치료용 조성물 |
| KR102272910B1 (ko) | 2021-01-28 | 2021-07-06 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
| KR20220140960A (ko) | 2021-04-12 | 2022-10-19 | 주식회사 아리바이오 | 당뇨병을 동반한 치매 예방 및 치료용 조성물 |
| KR102311224B1 (ko) | 2021-04-23 | 2021-10-13 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
| KR20220146095A (ko) | 2021-04-23 | 2022-11-01 | 주식회사 아리바이오 | Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
| DE3770095D1 (de) | 1986-08-21 | 1991-06-20 | Pfizer | Chinazolindione und pyridopyrimidindione. |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| US5264437A (en) | 1992-03-20 | 1993-11-23 | Syntex (U.S.A.) Inc. | Optionally substituted pyrido[2,3-d]pyridine-2,4(1H,3H)-diones and pyrido[2,]pyrimidine-2(1H,3H)-ones |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| CA2268190A1 (en) | 1997-08-06 | 1999-02-18 | Suntory Limited | 1-aryl-1,8-naphthylidin-4-one derivative as type iv phosphodiesterase inhibitor |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| WO2000045800A2 (en) | 1999-02-02 | 2000-08-10 | K.U. Leuven Research & Development | Immunosurpressive effects of pteridine derivatives |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| MXPA02012903A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como inhibidores de angiogenesis. |
| DE10050995A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| KR100831534B1 (ko) | 2001-04-30 | 2008-05-22 | 글락소 그룹 리미티드 | 17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체 |
| CA2447765C (en) | 2001-05-24 | 2011-01-25 | Merck Frosst Canada & Co./Merck Frosst Canada & Cie | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| US20030229058A1 (en) | 2001-11-13 | 2003-12-11 | Moran Edmund J. | Aryl aniline beta2 adrenergic receptor agonists |
| MXPA04007737A (es) * | 2002-02-11 | 2004-10-15 | Pfizer | Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4. |
| AU2003201745A1 (en) * | 2002-02-11 | 2003-09-04 | Pfizer Limited | Nicotinamide derivatives and a tiotropium salt in combination for the treatment of e.g. inflammatory, allergic and respiratory diseases |
| DE10216339A1 (de) | 2002-04-13 | 2003-10-23 | Boehringer Ingelheim Pharma | Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
| ES2302938T3 (es) | 2002-10-11 | 2008-08-01 | Pfizer Inc. | Derivados de indol como agonistas beta-2. |
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| AU2003286024A1 (en) | 2002-11-22 | 2004-06-18 | Daniel Dube | Use of phosphodiesterase-4 inhibitors as enhancers of cognition |
| IS7839A (is) | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
| US6909002B2 (en) * | 2002-11-22 | 2005-06-21 | Merck & Co., Inc. | Method of preparing inhibitors of phosphodiesterase-4 |
| WO2004105698A2 (en) | 2003-05-29 | 2004-12-09 | Merck & Co., Inc. | Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US7153870B2 (en) * | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317516D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317509D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317471D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Novel compounds |
| US7132435B2 (en) * | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
| GB0317484D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| CA2533786A1 (en) * | 2003-07-28 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| EP1651222A1 (en) * | 2003-07-29 | 2006-05-03 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| KR100747401B1 (ko) * | 2003-09-03 | 2007-08-08 | 화이자 인코포레이티드 | 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물 |
| US20090246281A1 (en) | 2003-11-03 | 2009-10-01 | Norton Healthcare Ltd. | Soft steroid compositions for use in dry powder inhalers |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| US20090093485A1 (en) | 2004-10-29 | 2009-04-09 | Astrazeneca Ab | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases |
| EP1981885A2 (en) | 2005-10-27 | 2008-10-22 | Merck & Co., Inc. | A method of preparing a 4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor |
| WO2007101213A2 (en) | 2006-02-28 | 2007-09-07 | Kalypsys, Inc. | Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors |
| TW200800997A (en) * | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
-
2009
- 2009-05-26 MX MX2010012492A patent/MX2010012492A/es active IP Right Grant
- 2009-05-26 BR BRPI0912103-0A patent/BRPI0912103A2/pt not_active Application Discontinuation
- 2009-05-26 KR KR1020107026555A patent/KR101605576B1/ko not_active Expired - Fee Related
- 2009-05-26 CN CN2009801293473A patent/CN102105448B/zh not_active Expired - Fee Related
- 2009-05-26 EP EP09754139.5A patent/EP2297106B1/en not_active Not-in-force
- 2009-05-26 TW TW098117462A patent/TW200951139A/zh unknown
- 2009-05-26 EP EP14171857.7A patent/EP2778156B8/en not_active Not-in-force
- 2009-05-26 CA CA2721065A patent/CA2721065C/en not_active Expired - Fee Related
- 2009-05-26 PT PT97541395T patent/PT2297106E/pt unknown
- 2009-05-26 HR HRP20140884AT patent/HRP20140884T1/hr unknown
- 2009-05-26 US US12/471,599 patent/US8273774B2/en not_active Expired - Fee Related
- 2009-05-26 RU RU2010149496/04A patent/RU2509077C2/ru active
- 2009-05-26 DK DK09754139.5T patent/DK2297106T3/da active
- 2009-05-26 AU AU2009252938A patent/AU2009252938B2/en not_active Ceased
- 2009-05-26 WO PCT/GB2009/050566 patent/WO2009144494A1/en not_active Ceased
- 2009-05-26 PL PL09754139T patent/PL2297106T3/pl unknown
- 2009-05-26 SI SI200930997T patent/SI2297106T1/sl unknown
- 2009-05-26 JP JP2011511094A patent/JP5607032B2/ja not_active Expired - Fee Related
- 2009-05-26 ES ES09754139.5T patent/ES2502527T3/es active Active
- 2009-05-27 UY UY0001031849A patent/UY31849A/es unknown
- 2009-05-27 AR ARP090101896A patent/AR071920A1/es unknown
- 2009-05-27 CL CL2009001298A patent/CL2009001298A1/es unknown
- 2009-05-27 PE PE2009000741A patent/PE20100144A1/es not_active Application Discontinuation
-
2011
- 2011-09-07 HK HK15102697.5A patent/HK1203482A1/en unknown
-
2014
- 2014-09-17 CY CY20141100759T patent/CY1115566T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011521938A5 (enExample) | ||
| KR102246652B1 (ko) | 암 치료용 화합물 | |
| JP2014505660A5 (enExample) | ||
| JP2013510123A5 (enExample) | ||
| RU2016146365A (ru) | Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b | |
| CA2687265A1 (en) | P70 s6 kinase inhibitors | |
| JP2010526814A5 (enExample) | ||
| JP2010511626A5 (enExample) | ||
| ES2718637T3 (es) | Compuestos para el tratamiento del cáncer | |
| JP2010535233A5 (enExample) | ||
| JP2007502807A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| RU2010149496A (ru) | Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний | |
| CN105120868A (zh) | 组合治疗 | |
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| JP2014505107A5 (enExample) | ||
| RU2009104764A (ru) | Производные пурина, как антангонисты a2a | |
| RU2013136895A (ru) | Новое бициклическое соединение или его соль | |
| RU2013136861A (ru) | Новое производное индола или индазола или его соль | |
| RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний | |
| RU2010154417A (ru) | Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств | |
| RU2015101702A (ru) | Фармацевтически активные соединения | |
| JP2014532063A5 (enExample) | ||
| JP2019516726A5 (enExample) |